Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 9, 2010, Pages 1621-1627

  Calvo, Jose A ^a   Miskulin, Dana C ^a   Meyer, Klemens B ^a   Weiner, Daniel E ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CONFIDENCE INTERVAL; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; TREATMENT OUTCOME;

AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 77957327458     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02650310     Document Type: Article

References (36)

1. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148, 1989 (Pubitemid 19047434)
2. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111: 992-1000, 1989 (Pubitemid 20034923)
3. Sikole A, Polenakovic M, Spirovska V, Polenakovic B, Masin G: Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs 17: 977-984, 1993 (Pubitemid 24025978)
4. Wizemann V, Schafer R, Kramer W: Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 64: 202-206, 1993 (Pubitemid 23153047)
5. Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P: Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: A meta-analysis. Clin J Am Soc Nephrol 4: 755-762, 2009
6. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578, 1990
7. Macdougall IC, Lewis NP, Saunders MJ, Cochlin DL, Davies ME, Hutton RD, Fox KA, Coles GA, Williams JD: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335: 489-493, 1990 (Pubitemid 20073052)
8. Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW: Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 15: 325-332, 1990 (Pubitemid 20257471)
9. Pfeffer MA: Critical missing data on erythropoiesis-stimulating agents in CKD: First beat placebo. Am J Kidney Dis 51: 366-369, 2008
10. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998 (Pubitemid 28385655)
11. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
12. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
13. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
14. Ebben JP, Gilbertson DT, Foley RN, Collins AJ: Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol 1: 1205-1210, 2006
15. Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ: Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 3: 133-138, 2008
16. Department of Health and Human Services. Centers for Medicare & Medicaid Services: End-stage renal disease prospective payment system proposed rules. Fed Reg 74: FR49922-FR50102, 2009
17. Department of Health & Human Services Center for Medicare and Medicaid Services: Pub 100-04 Medicare claims processing. National Monitoring Policy for EPO and Aranesp for end stage renal disease (ESRD) patients treated in renal dialysis facilities. Available at www.cms.hhs.gov/CoverageGenInfo/ Downloads/ESA04012006.pdf. Accessed March 22, 2010
18. KDOQI: KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 50: 471-530, 2007
19. Epoetin alfa (marketed as Epoetin, Procrit) Label, 2/16/10. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/103234s5199lbl.pdf. Accessed March 1, 2010
20. Weiner DE, Miskulin DC, Seefeld K, Ladik V, Zager PG, Singh AK, Johnson HK, Meyer KB: Reducing versus discontinuing erythropoietin at high hemoglobin levels. J Am Soc Nephrol 18: 3184-3191, 2007 (Pubitemid 350223979)
21. Polenakovic M, Sikole A: Is erythropoietin a survival factor for red blood cells? J Am Soc Nephrol 7: 1178-1182, 1996 (Pubitemid 27468270)
22. Miskulin DC, Weiner DE, Tighiouart H, Ladik V, Servilla K, Zager PG, Martin A, Johnson HK, Meyer KB: Computerized decision support for EPO dosing in hemodialysis patients. Am J Kidney Dis 54: 1081-1088, 2009
23. Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 17: 1181-1191, 2006
24. Messana JM, Chuang CC, Turenne M, Wheeler J, Turner J, Sleeman K, Tedeschi P, Hirth R: Association of quarterly average achieved hematocrit with mortality in dialysis patients: A time-dependent comorbidity-adjusted model. Am J Kidney Dis 53: 503-512, 2009
25. Weiner DE, Watnick SG: The 2009 proposed rule for prospective ESRD payment: Historical perspectives and public policies - bundle up! Am J Kidney Dis 55:217-222, 2010
26. Levinson DR: Department of Health and Human Services Office of the Inspector General. Medicare reimbursement for end stage renal disease drugs: Third quarter 2006. Available at: http://www.oig.hhs.gov/oei/reports/oei-03-06- 00590.pdf. Accessed June 1, 2010
27. Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB: Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int 64: 1514-1521, 2003
28. Fried W: Erythropoietin and erythropoiesis. Exp Hematol 37: 1007-1015, 2009
29. Rice L, Alfrey CP: The negative regulation of red cell mass by neocytolysis: Physiologic and pathophysiologic manifestations. Cell Physiol Biochem 15: 245-250, 2005 (Pubitemid 41022626)
30. Ross RP, McCrea JB, Besarab A: Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO J 40: M880-885, 1994
31. Kato A, Hishida A, Kumagai H, Furuya R, Nakajima T, Honda N: Erythropoietin production in patients with chronic renal failure. Renal Failure 16: 645-651, 1994 (Pubitemid 24371326)
32. Chandra M, Clemons GK, McVicar MI: Relation of serum erythropoietin levels to renal excretory function: Evidence for lowered set point for erythropoietin production in chronic renal failure. J Pediatr 113: 1015-1021, 1988 (Pubitemid 19014250)
33. Rice L, Alfrey CP, Driscoll T, Whitley CE, Hachey DL, Suki W: Neocytolysis contributes to the anemia of renal disease. Am J Kidney Dis 33: 59-62, 1999 (Pubitemid 29031209)
34. Means RT Jr: Neocytolysis: from outer space to the dialysis unit. Am J Kidney Dis 33: 140-141, 1999
35. Fishbane S, Berns JS: Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 68: 1337-1343, 2005 (Pubitemid 43246455)
36. Collins AJ, Ebben JP, Gilbertson DT: EPO adjustments in patients with elevated hemoglobin levels: Provider practice patterns compared with recommended practice guidelines. Am J Kidney Dis 49: 135-142, 2007